Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Overview of the Drug Development Landscape

Discussion in 'General ME/CFS News' started by lnester7, Mar 26, 2013.

  1. lnester7

    lnester7 Seven

    Messages:
    1,737
    Likes:
    1,912
    USA
    http://www.research1st.com/2013/03/18/upcoming-webinar-1/

    Date/Time: March 28, 2013 at 1:00 p.m. EDT
    Speaker: Kristin Schneeman, Program Director, FasterCures Host: Kim McCleary, CEO, The CFIDS Association of America
    Registration: http://bit.ly/spring-series-1

    In the first program of our Spring 2013 Webinar Series, we welcome Kristin Schneeman, program director for FasterCures, as our guest speaker. Kristin will outline the process to translate scientific discoveries into accessible medical solutions. She will define the major components of the research and development (R&D) cycle as a basis for helping community members understand the landscape for drug development. She will contrast it with the landscape for basic research, an area that is more familiar to most patient advocates and community members.
     

See more popular forum discussions.

Share This Page